AbbVie Inc. (ABBV) Receives Buy Rating from Jefferies Group LLC

Jefferies Group LLC reissued their buy rating on shares of AbbVie Inc. (NYSE:ABBV) in a research note published on Friday morning. They currently have a $107.00 price objective on the stock, up from their previous price objective of $94.00.

Several other equities research analysts have also weighed in on the company. Piper Jaffray Companies reiterated a buy rating and issued a $100.00 price objective on shares of AbbVie in a research note on Friday. SunTrust Banks, Inc. reiterated a buy rating and issued a $95.00 price objective on shares of AbbVie in a research note on Wednesday. Leerink Swann reiterated a market perform rating on shares of AbbVie in a research note on Tuesday. Cowen and Company reiterated a hold rating and issued a $95.00 price objective (up from $70.00) on shares of AbbVie in a research note on Monday, September 11th. Finally, Goldman Sachs Group, Inc. (The) reiterated a buy rating and issued a $100.00 price objective (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie presently has a consensus rating of Buy and a consensus target price of $82.38.

AbbVie (NYSE ABBV) traded down 2.07% on Friday, reaching $87.37. The company had a trading volume of 20,441,496 shares. The company has a 50-day moving average of $74.86 and a 200 day moving average of $69.44. The stock has a market cap of $139.28 billion, a price-to-earnings ratio of 21.49 and a beta of 1.48. AbbVie has a one year low of $55.06 and a one year high of $89.69.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same period in the prior year, the company posted $1.26 EPS. The company’s revenue was up 7.6% compared to the same quarter last year. On average, equities research analysts predict that AbbVie will post $5.52 EPS for the current year.

TRADEMARK VIOLATION WARNING: “AbbVie Inc. (ABBV) Receives Buy Rating from Jefferies Group LLC” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2017/09/16/abbvie-inc-abbv-receives-buy-rating-from-jefferies-group-llc.html.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s dividend payout ratio is 62.90%.

In other AbbVie news, insider Henry O. Gosebruch sold 18,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the transaction, the insider now owns 96,074 shares of the company’s stock, valued at approximately $6,733,826.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at approximately $7,915,276.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 373,191 shares of company stock worth $26,598,305. Company insiders own 0.23% of the company’s stock.

A number of large investors have recently bought and sold shares of ABBV. Vanguard Group Inc. lifted its holdings in AbbVie by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock worth $8,405,409,000 after buying an additional 3,706,941 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of AbbVie by 1,949.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after purchasing an additional 3,646,510 shares during the period. Orbis Allan Gray Ltd lifted its stake in shares of AbbVie by 35.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after purchasing an additional 3,340,038 shares during the period. Capital Research Global Investors lifted its stake in shares of AbbVie by 1.2% in the 2nd quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after purchasing an additional 2,130,919 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of AbbVie by 2.0% in the 2nd quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after purchasing an additional 1,864,418 shares during the period. 68.29% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply